Trident Lifeline

Trident Lifeline

312.00
-0.10
(-0.03%)
hide
Key Fundamentals
Add Ratio
Market Cap
361.68 Cr
EPS
10.22
PE Ratio
21.84
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
324.95
52 Week Low
222.00
PB Ratio
4.47
Debt to Equity
0.62
Forecast For
Actual

Company News

View All News
Caret
neutral
Trident Lifeline Rectifies Trade Payables Disclosure in Half-Year Results5 days ago
Trident Lifeline Limited corrected discrepancies in trade payables bifurcation for its half-year results ended September 30, 2025, following BSE's notification on November 13, 2025. The company reported standalone net profit of Rs 841.27 lakhs and consolidated net profit of Rs 801.13 lakhs for the half-year period, with revenue from operations at Rs 4,625.86 lakhs (standalone) and Rs 5,335.68 lakhs (consolidated).
positive
Trident Lifeline Limited announced its unaudited financial results for the half year ended September 30, 2025. The company's revenue from operations increased to ₹46.26 crores compared to ₹30.40 crores in the same period last year. Net profit rose to ₹8.42 crores from ₹6.40 crores year-over-year. On a consolidated basis, revenue reached ₹53.36 crores versus ₹29.25 crores previously, with consolidated net profit at ₹8.01 crores compared to ₹5.39 crores. The company's earnings per share improved to ₹7.26 from ₹5.57 in the corresponding period. The Board of Directors approved these results at their meeting held on November 11, 2025. The company operates through multiple subsidiaries including TNS Pharma Private Limited, TLL Parenterals Limited, Trident Mediquip Limited, TLL Elements Private Limited, and TLL Herbal Limited.
positive
Trident Lifeline Limited reported quarterly revenue of ₹1,935.48 lakh, marking 27% year-over-year growth. The pharmaceutical company's EBITDA increased 20% to ₹546.36 lakh with margins at 28%. Profit after tax grew 15% to ₹347.59 lakh, while earnings per share reached ₹3.02. The company operates across 43 countries with 1,035 export market products registered and 2,329 registrations in process. Trident maintains a hybrid manufacturing model combining own facilities and contract manufacturing, with presence in African, Latin American, CIS and East Asian markets. The company's product portfolio spans 3,364 products across multiple therapeutic categories including tablets, capsules, syrups and ointments.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,784.10
#1 4,28,065.35
40.27
#1 54,729.00
9.71
#1 10,980
2.89
74.53
6,454.00
1,71,333.42
69.17
9,712.00
18.67
2,191
35.10
46.81
3,731.40
1,26,287.53
59.99
11,539.40
6.99
1,911
30.46
56.17
1,526.80
1,23,327.89
22.52
28,409.50
7.12
5,291
3.71
47.29
1,250.20
1,04,343.41
#1 18.09
33,741.20
16.73
5,725
-0.38
54.25
930.20
93,599.89
18.57
23,511.00
18.55
4,615
34.60
33.90
2,025.40
92,511.06
21.51
22,909.50
13.74
3,306
#1 72.75
57.78
2,223.10
91,760.34
51.75
12,744.20
#1 20.90
2,007
-21.05
29.21
1,235.80
71,775.46
21.23
32,345.60
9.43
3,484
3.81
74.03
5,724.00
68,439.01
28.33
13,458.30
3.70
2,216
10.98
64.07
Growth Rate
Revenue Growth
103.85 %
Net Income Growth
77.97 %
Cash Flow Change
-559.19 %
ROE
36.88 %
ROCE
23.42 %
EBITDA Margin (Avg.)
10.32 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
9
6
8
10
9
9
10
7
21
14
16
12
36
25
31
Expenses
7
5
6
7
7
7
8
6
17
11
11
8
26
18
23
EBITDA
2
1
2
2
3
2
3
2
4
4
5
5
10
7
9
Operating Profit %
20 %
14 %
18 %
21 %
23 %
20 %
22 %
20 %
12 %
19 %
26 %
34 %
25 %
22 %
23 %
Depreciation
0
0
0
0
0
0
0
0
0
1
0
1
3
2
1
Interest
0
0
0
0
0
0
0
0
0
1
1
1
2
1
1
Profit Before Tax
2
1
2
2
2
2
2
1
3
3
4
4
6
4
7
Tax
-1
0
0
0
0
1
1
0
1
1
1
1
0
1
2
Net Profit
3
1
1
2
2
1
2
1
2
2
3
3
6
3
5
EPS in ₹
15.02
0.88
1.15
1.77
1.72
1.22
1.48
0.94
1.41
1.99
2.69
2.42
6.15
2.66
4.27

Balance Sheet

Balance Sheet
2022
2023
2024
2025
Total Assets
14
63
87
156
Fixed Assets
1
3
21
44
Current Assets
11
49
52
90
Capital Work in Progress
0
5
4
2
Investments
0
0
0
0
Other Assets
12
55
62
111
Total Liabilities
14
63
87
156
Current Liabilities
8
12
20
54
Non Current Liabilities
2
4
13
33
Total Equity
5
47
54
70
Reserve & Surplus
-3
34
40
53
Share Capital
8
12
12
12

Cash Flow

Cash Flow
2022
2023
2024
2025
Net Cash Flow
0
14
-7
-4
Investing Activities
-0
-10
-20
-14
Operating Activities
-0
-19
2
-10
Financing Activities
1
42
11
20

Share Holding

% Holding
Aug 2022
Sept 2022
Oct 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
100.00 %
69.57 %
69.57 %
69.85 %
69.99 %
70.04 %
70.04 %
70.04 %
67.48 %
65.51 %
62.99 %
62.99 %
63.04 %
63.04 %
63.11 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
4.64 %
6.02 %
6.02 %
6.09 %
6.09 %
6.62 %
7.21 %
7.71 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.09 %
0.39 %
0.41 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
23.18 %
23.18 %
15.13 %
13.38 %
14.30 %
14.82 %
14.43 %
16.39 %
18.37 %
19.40 %
18.90 %
18.26 %
17.90 %
17.63 %
Others
0.00 %
7.25 %
7.25 %
15.02 %
16.63 %
15.66 %
15.14 %
10.88 %
10.10 %
10.10 %
11.52 %
12.02 %
11.99 %
11.45 %
11.14 %
No of Share Holders
0
10
1,389
397
388
387
439
481
500
502
507
523
534
549
554

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
20 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
20 Sept 2024 266.00 314.00
19 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
19 Oct 2024 284.95 299.00
22 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
22 Jan 2025 266.00 281.50
28 Apr 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Apr 2025 270.00 284.00
09 May 2025 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
09 May 2025 252.65 287.00
28 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jul 2025 270.00 273.20
27 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
27 Sept 2025 297.05 296.00
11 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Nov 2025 296.50 300.75

Announcements

Revised Unaudited Financial Results For The Half Year Ended September 30 2025.5 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication6 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation6 days ago
Result-Financial Result For The Half Year Ended 30.09.20258 days ago
Board Meeting Outcome for Outcome Of Board Meeting Held On 11.11.20258 days ago
Board Meeting Intimation for Declaration Of Un-Audited Result For Half Year Ended 30.09.2025Nov 04, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Closure of Trading WindowSep 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 29, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 06, 2025
Reg. 34 (1) Annual Report.Sep 05, 2025
Notice Of 12Th Annual General Meeting Of The CompanySep 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Intimation Of Book Closure And Cut-Off Date For 12Th AGMSep 01, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateSep 01, 2025
Annual General Meeting Scheduled To Be Held On 27.09.2025Sep 01, 2025
Outcome Of Board MeetingSep 01, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 01St September 2025Sep 01, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 30, 2025
Statement Of Deviation For The Quarter Ended June 302025Jul 28, 2025
Appointment Of Secretarial Auditor Of The Company For The First Term From Financial Year 2025-26 To FY 2029-30 Subject To Approval Of The Members In Ensuing AGMJul 28, 2025
Financial Result For The Quarter Ended June 2025Jul 28, 2025
Board Meeting Outcome for For Financial Result For Quarter Ended June 30 2025Jul 28, 2025
Board Meeting Outcome for For Financial Result For Quarter Ended June 30 2025Jul 28, 2025
Board Meeting Intimation for Consideration Of Un-Audited Financial Results For The Quarter Ended June 30 2025Jul 22, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 04, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 04, 2025
Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeover) Regulations 2011Jul 03, 2025
Announcement under Regulation 30 (LODR)-AllotmentJul 01, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E. On July 01 2025 In Terms Of Second Proviso To Regulation 30(6) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 01, 2025
Closure of Trading WindowJun 28, 2025
Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeover) Regulations 2011Jun 12, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Announcement under Regulation 30 (LODR)-AllotmentJun 09, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E. On June 09 2025 In Terms Of Second Proviso To Regulation 30(6) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 09, 2025
Announcement Under Regulation 30- Cessation Of Corporate OfficeMay 19, 2025
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 -Launch Of New Skin Care Brand YES By Subsidiary Company- TLL Elements Private LimitedMay 12, 2025
Scrutinizer"S ReportMay 12, 2025

Technical Indicators

RSI(14)
Neutral
55.60
ATR(14)
Less Volatile
10.62
STOCH(9,6)
Neutral
63.95
STOCH RSI(14)
Neutral
74.85
MACD(12,26)
Bullish
0.81
ADX(14)
Weak Trend
18.20
UO(9)
Bearish
55.38
ROC(12)
Uptrend And Accelerating
7.60
WillR(14)
Neutral
-30.99